Patent intelligence · US
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
Patent details — US 11071729
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 27, 2021
- Expiration
- Jul 22, 2041
- Applicant
- Addex Pharmaceuticals S.A.
- Claims
- 20
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/5377
Quick answer
US 11071729 (1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones) is held by Addex Pharmaceuticals S.A.. Status: granted. Granted Jul 27, 2021. Expires Jul 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharmaceuticals S.A.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/5377, A61K45/06, A61K47/10
More from Addex Pharmaceuticals S.A.
Related pharmaceutical patents in our USPTO index.
-
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 11071729?
US 11071729 (1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones) is held by Addex Pharmaceuticals S.A.. Status: granted. Granted Jul 27, 2021. Expires Jul 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11071729?
Addex Pharmaceuticals S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11071729 expire?
Our index shows an expiration date of Jul 22, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.